carboplatin + celecoxib + gemcitabine + zileuton

This drug is a combination therapy consisting of four agents used primarily in cancer treatment and asthma management. - **Carboplatin** is a platinum-based chemotherapy agent that causes DNA crosslinking, leading to apoptosis of cancer cells. It is commonly used for ovarian, lung, and other cancers. - **Celecoxib** is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces inflammation and may enhance chemotherapy efficacy by sensitizing tumor cells to platinum-based drugs like carboplatin. It has been studied in recurrent ovarian cancer and other malignancies. - **Gemcitabine** is a nucleoside analog chemotherapeutic agent that inhibits DNA synthesis by incorporation into DNA strands, causing chain termination. It treats various advanced cancers including ovarian, breast, lung, and pancreatic cancers often in combination with platinum agents. - **Zileuton** is a leukotriene synthesis inhibitor targeting the enzyme 5-lipoxygenase to reduce leukotriene-mediated inflammation; it is primarily used for long-term management of asthma but may have adjunctive roles due to its anti-inflammatory properties.